Wall Street analysts expect Tenet Healthcare (NYSE:THC) to post sales of $4.59 billion for the current fiscal quarter, according to Zacks. Eight analysts have issued estimates for Tenet Healthcare’s earnings, with the lowest sales estimate coming in at $4.52 billion and the highest estimate coming in at $4.68 billion. Tenet Healthcare posted sales of $4.81 billion during the same quarter last year, which suggests a negative year over year growth rate of 4.6%. The business is scheduled to issue its next earnings report after the market closes on Monday, April 30th.

On average, analysts expect that Tenet Healthcare will report full-year sales of $18.09 billion for the current financial year, with estimates ranging from $17.92 billion to $18.21 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $18.15 billion per share, with estimates ranging from $16.67 billion to $18.93 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Tenet Healthcare.

Tenet Healthcare (NYSE:THC) last posted its earnings results on Monday, February 26th. The company reported $1.40 EPS for the quarter, topping the Zacks’ consensus estimate of $1.25 by $0.15. The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.85 billion. Tenet Healthcare had a positive return on equity of 9.69% and a negative net margin of 3.67%. The company’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.06 EPS.

THC has been the subject of a number of research analyst reports. Wells Fargo initiated coverage on Tenet Healthcare in a report on Tuesday, January 30th. They issued a “market perform” rating and a $20.00 target price for the company. Zacks Investment Research raised Tenet Healthcare from a “sell” rating to a “hold” rating in a report on Tuesday, March 13th. SunTrust Banks reaffirmed a “hold” rating on shares of Tenet Healthcare in a report on Thursday, March 1st. Goldman Sachs started coverage on Tenet Healthcare in a report on Wednesday, January 3rd. They issued a “neutral” rating and a $15.00 price objective for the company. Finally, Citigroup lifted their price objective on Tenet Healthcare from $19.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, March 1st. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $22.19.

In other Tenet Healthcare news, Director George Fredrick Smitherman sold 14,300 shares of the business’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $2.02, for a total transaction of $28,886.00. Also, Director Ashish Dave sold 75,000 shares of the business’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $1.40, for a total value of $105,000.00. Insiders have sold 128,300 shares of company stock valued at $149,096 in the last three months. 1.20% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in THC. Letko Brosseau & Associates Inc. bought a new stake in Tenet Healthcare during the fourth quarter valued at about $30,300,000. Millennium Management LLC purchased a new position in shares of Tenet Healthcare in the fourth quarter valued at about $22,655,000. Price Michael F purchased a new position in shares of Tenet Healthcare in the fourth quarter valued at about $6,064,000. Dimensional Fund Advisors LP lifted its position in shares of Tenet Healthcare by 18.2% in the third quarter. Dimensional Fund Advisors LP now owns 2,530,802 shares of the company’s stock valued at $41,579,000 after acquiring an additional 389,144 shares in the last quarter. Finally, Gotham Asset Management LLC lifted its position in shares of Tenet Healthcare by 446.4% in the fourth quarter. Gotham Asset Management LLC now owns 439,274 shares of the company’s stock valued at $6,659,000 after acquiring an additional 358,885 shares in the last quarter.

Shares of Tenet Healthcare stock traded down $0.38 on Wednesday, reaching $24.09. The company’s stock had a trading volume of 1,100,067 shares, compared to its average volume of 1,867,128. The firm has a market cap of $2,474.11, a price-to-earnings ratio of 29.74, a PEG ratio of 2.06 and a beta of 0.80. Tenet Healthcare has a 52 week low of $12.25 and a 52 week high of $25.24. The company has a current ratio of 1.29, a quick ratio of 1.22 and a debt-to-equity ratio of 27.44.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2018/04/21/analysts-anticipate-tenet-healthcare-thc-will-post-quarterly-sales-of-4-59-billion.html.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation operates as a diversified healthcare services company. It operates in three segments: Hospital Operations and Other, Ambulatory Care, and Conifer. The company's general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.

Get a free copy of the Zacks research report on Tenet Healthcare (THC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tenet Healthcare (NYSE:THC)

Receive News & Ratings for Tenet Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenet Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.